January 30, 2023
2 min watch
Moss A. Presentation Sp161: Therapeutic drug monitoring of IBD. Offered at: Crohn’s and Colitis Congress; Jan. 19-21, 2023; Denver (hybrid assembly).
Moss reviews no related monetary disclosures.
DENVER — In a Healio video unique, Alan Moss, MD, discusses his presentation on the Crohn’s and Colitis Congress, which detailed using therapeutic drug monitoring within the administration of sufferers with inflammatory bowel illness.
Talking to attendees, Moss, director of the Crohn’s & Colitis program at Boston Medical Middle, centered on three areas: the rationale and proof behind therapeutic drug monitoring (TDM), shifts in understanding how TDM might be utilized into observe and proof supporting utilizing TDM proactively or reactively in affected person care, and new improvements in combining pharmacodynamics with pharmacokinetic monitoring to supply a “smarter” model of TDM.
“This incorporates point-of-care assays, assays for drug ranges and dashboards that permit you are expecting the greatest time and the most effective dose to your affected person’s subsequent infusion or therapy,” Moss stated.